Back to Search
Start Over
Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas.
- Source :
- Frontiers in Oncology; 11/13/2019, p1-4, 4p
- Publication Year :
- 2019
-
Abstract
- Keywords: primary cutaneous lymphomas; aggressive cutaneous B cell lymphomas; rituximab; target therapy; new monoclonal antibodies Rituximab monotherapy was proven effective in primary cutaneous low-grade B cell lymphomas, whereas the ESMO clinical practice guidelines indicate immunochemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) as first-line treatment for PCDLBCL-LT ([10]). 5 Pham-Ledard, A, Prochazkova-Carlotti, M, Andrique, L, Cappellen, D, Vergier, B, Martinez, F, Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Primary cutaneous lymphomas, aggressive cutaneous B cell lymphomas, rituximab, target therapy, new monoclonal antibodies. [Extracted from the article]
- Subjects :
- CUTANEOUS T-cell lymphoma
B cell lymphoma
LYMPHOMAS
MANTLE cell lymphoma
NF-kappa B
Subjects
Details
- Language :
- English
- ISSN :
- 2234943X
- Database :
- Complementary Index
- Journal :
- Frontiers in Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 139649249
- Full Text :
- https://doi.org/10.3389/fonc.2019.01238